Rapirosiran

Rapirosiran is a N-acetylgalactosamine-conjugated small-interfering RNA targeting liver-expressed hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) mRNA. Loss-of-function variants in the HSD17B13 associated with reduced risk of chronic liver disease. Rapirosiran can be used for the study of Non-alcoholic steatohepatitis.

Product Specifications

CAS Number

[2755196-97-3]

Product Name Alternative

ALN-HSD; ALN-288996; AD-288996

UNSPSC

12352211

Target

17β-HSD

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Metabolic Disease

Smiles

[Rapirosiran]

Molecular Formula

C530H719F7N171O323P43S6

Molecular Weight

16307.22

References & Citations

[1]Sanyal AJ, Taubel J, Badri P, et al. Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis. J Hepatol. 2025;83 (4) :838-848.